Monograph Details
|
|
Neoplasms
> Alkylating agents
|
|
Cisplatin |
| Manufacturer |
|
Various generic manufacturers |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Platinum coordination complex. |
| Generic Name |
|
Cisplatin 1mg/mL; soln for IV infusion after dilution. |
| Indications |
|
As a single agent, for treating transitional cell bladder cancer or for secondary therapy of metastatic ovarian tumor. Adjunctive therapy for metastatic testicular or ovarian tumor. |
| Children |
|
Not recommended. |
| Adults |
|
Give by IV infusion over 6–8 hours. Bladder: 50–70mg/m2 IV per cycle once every 3–4 weeks; heavily pretreated patients: initially 50mg/m2 IV per cycle every 4 weeks. Testicular: 20mg/m2 IV daily for 5 days per cycle. Ovarian: 100mg/m2 IV per cycle once every 4 weeks; or, (when given with cyclophosphamide): 75–100mg/m2 IV per cycle once every 4 weeks. Usual max: 100mg/m2 per cycle. Subsequent cycles: give as tolerated, withhold dose if serum creatinine, BUN, platelets, WBCs, or auditory acuity out of normal limits; see literature. |
| Contraindications |
|
Renal or hearing impairment. Myelosuppression. Pregnancy (Cat.D). Nursing mothers. |
| Precautions |
|
Have epinephrine, antihistamine available. Monitor baseline and pre-treatment renal function, electrolytes, auditory function; do periodic CBCs (weekly), liver function tests, neurologic exam. Hydrate patient before dosing. Avoid extravasation. Elderly. |
| Interactions |
|
Potentiates nephrotoxicity with other nephrotoxic drugs (eg, aminoglycosides). May antagonize anticonvulsants. May be antagonized by pyridoxine. |
| Adverse Reactions |
|
Nephrotoxicity, neurotoxicity (eg, peripheral neuropathies), ototoxicity, myelosuppression, hemolytic anemia, marked nausea and vomiting, vascular toxicity (eg, MI, TIA), electrolyte disturbances, hyperuricemia, SIADH, hepatotoxicity, anaphylactic-like reactions, others; see literature. |
| Extra Text |
|
Note: Avoid contact with aluminum (eg, needles). |
| How Supplied |
|
Contact supplier. |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
